Bimagrumab

GLP-1 drugs like Wegovy and Zepbound can lead to significant weight loss but may also cause muscle loss. Researchers are concerned about the impact on muscle mass and function, which can affect health and mobility. Strategies to preserve muscle include a protein-rich diet, regular exercise, and potentially using drugs that prevent muscle loss.

Eli Lilly and Laekna collaborate on an obesity drug, LAE102, targeting weight loss and muscle preservation. This move intensifies competition in the $150B obesity treatment market, dominated by Lilly and Novo Nordisk. Other companies like Regeneron and Scholar Rock are also developing muscle-preserving treatments, reflecting a growing focus on maintaining muscle mass during weight loss.

Weight-loss drugs like Wegovy and Ozempic are changing the world in unexpected ways, influencing fashion, Hollywood, social lives, the weight-loss industry, food industry, gyms, and even airlines, while also raising questions about mental health and body positivity.

New companies aim to challenge Eli Lilly and Novo Nordisk's dominance in the GLP-1 weight-loss drug market, projected to reach $200 billion by 2031. Emerging competitors like Roche, Amgen, Pfizer, and AstraZeneca focus on enhanced efficacy and convenience to disrupt the market. By 2029, 16 new drugs are expected to enter the market, adding $70 billion to the segment. Despite pricing challenges and limited international penetration, GLP-1 drugs are expected to see significant usage in the U.S., with Novo and Lilly maintaining a strong market presence through pipeline advancements.